AstraZeneca: to recover global rights on brazikumab
(CercleFinance.com) - AstraZeneca will recover the global rights to brazikumab from Allergan, with the deal set to be completed in the first three months of 2020.
AstraZeneca and Allergan will terminate their existing license agreement and all rights to brazikumab will return to AstraZeneca.
Allergan will finance up to an agreed amount, estimated at the total costs expected to be incurred by AstraZeneca until the development of brazikumab in CD and UC is completed, including the development of a companion diagnosis.
Brazikumab is currently undergoing a phase IIb / III program in Crohn's disease (CD) and a phase IIb trial in ulcerative colitis (UC).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
AstraZeneca and Allergan will terminate their existing license agreement and all rights to brazikumab will return to AstraZeneca.
Allergan will finance up to an agreed amount, estimated at the total costs expected to be incurred by AstraZeneca until the development of brazikumab in CD and UC is completed, including the development of a companion diagnosis.
Brazikumab is currently undergoing a phase IIb / III program in Crohn's disease (CD) and a phase IIb trial in ulcerative colitis (UC).
Copyright (c) 2020 CercleFinance.com. All rights reserved.